球体和类器官作为疾病建模和药物筛选的创新模型引起了广泛关注。通过使用不同类型的球体或类器官，建立微生理系统是可行的，该系统可以提高疾病建模的精度并提供更可靠和更全面的药物筛选。支持多种药物的可选并行测试的高通量微生理系统在个性化医疗和药物研究中具有广阔的应用前景。然而，建立这样一个系统非常具有挑战性，需要采用多学科方法。本研究介绍了一种动态微生理系统芯片平台 (MSCP)，其具有包含上述优点的多种功能微结构。我们开发了高通量肺癌球体模型和肠-肝-心-肺癌微生理系统，用于对四种抗肺癌药物进行平行测试，证明了MSCP的可行性。该微生理系统结合了微观和宏观仿生学，能够全面评估药物疗效和副作用。此外，微生理系统可以通过基于液体的生理通讯来评估药物分子在被正常器官吸收后到达目标病变部位的真实药理作用。 MSCP 可以作为微生理系统研究的宝贵平台，为疾病建模、药物开发和个性化医疗做出重大贡献。© 2024 作者。

Spheroids and organoids have attracted significant attention as innovative models for disease modeling and drug screening. By employing diverse types of spheroids or organoids, it is feasible to establish microphysiological systems that enhance the precision of disease modeling and offer more dependable and comprehensive drug screening. High-throughput microphysiological systems that support optional, parallel testing of multiple drugs have promising applications in personalized medical treatment and drug research. However, establishing such a system is highly challenging and requires a multidisciplinary approach. This study introduces a dynamic Microphysiological System Chip Platform (MSCP) with multiple functional microstructures that encompass the mentioned advantages. We developed a high-throughput lung cancer spheroids model and an intestine-liver-heart-lung cancer microphysiological system for conducting parallel testing on four anti-lung cancer drugs, demonstrating the feasibility of the MSCP. This microphysiological system combines microscale and macroscale biomimetics to enable a comprehensive assessment of drug efficacy and side effects. Moreover, the microphysiological system enables evaluation of the real pharmacological effect of drug molecules reaching the target lesion after absorption by normal organs through fluid-based physiological communication. The MSCP could serves as a valuable platform for microphysiological system research, making significant contributions to disease modeling, drug development, and personalized medical treatment.© 2024 The Authors.